The company has insisted on the strategy of new product innovation. The Research & Development (R&D) Centre has established for 20 years since the company founded. The company has set up an excellent research system, with more than 200 researchers. About 25% of them have doctoral degrees and about 70% have master degrees. One scientist in the Centre is supported by ‘Recruitment Programme of Global Experts’ (8th Group) and the other two are supported by ‘2012 Triple-three High Level Talents Programme’. The R&D Centre is consisted by nine departments, including Analytical Department, Biological Pharmaceutical Department, Medicinal Chemistry Departmemt, Scientifically Medical Department, Organic Process Department, Integrated Management Department, Formulation Department, Registration & Project Management Department and Pharmacology Toxicology Department.
The R&D centre is undertaking more than twenty important research projects supported by State and provincial government, including ‘Significant Novel Drug Innovation’ programme, State high-tech research & development programme, State innovation foundation, State key new products programme, State ‘Torch’ projects, and etc.. The R&D Centre has four state certificated research platforms: National innovation medicine incubation base for chiral anti-infection and targeting anti-tumour new drugs, National postdoctoral programme station, Jiangsu engineering technology R&D centre, and Jiangsu enterprise technology centre.
The R&D centre has achieved significant progresses in independent innovation. Currently, the company has submitted 99 national patent applications. 14 of them have been submitted for international PCT patents. The company has been awarded with 34 China patents and 8 overseas patents. So far, Sanhome has nearly one hundred new drugs, which have been licensed. Particularly, levornidazole and its pharmaceutical products have been certificated and licensed as 1st class (IND category) new drug by CFDA in China. The levornidazole research project has been awarded with ‘State Key New Product’ by Ministry of Science and Technology in 2010, ‘the most significant 10 innovative biomedical projects’ in Jiangsu in 2012, and ‘First class progress prize in scientific and collective technology’ by Jiangsu in 2014. Levornidazole itself has been awarded with ‘excellent branding product’ in Jiangsu in 2014, and the its patent has been awarded with ‘The 17th session of China excellent patent’ in 2015. Another 1st class novel drug, C118P, has been approved for clinical trial by China Food and Drug Administration, and it is currently undertaking phase I clinical trial.
To further improve the innovation ability, the company has set up a new R&D centre in Chilin Innovation Park for Sciences and Technology, and it has built up a new bio-pharmaceutical research lab by cooperating with the China Pharmaceutical University.
By the end of 2016, it will be expected that the number of R&D staffs will reach about 300. Further detailed studies in current research fields will make more people to enjoy healthy happiness.
Roman';line-height:150%;font-size:16px;mso-font-kerning:1px;" >